Dear Colleague,

Given the large amount of data being generated from clinical studies, it’s not much of a challenge to reach your clinical goals. But we also have the ability to get key insights at lower costs and faster than ever before.

However, there are two considerations:

       a)   Can this data change a patient’s behaviours?
       b)   Even if the FDA has approved the use of non-medical devices, is there a risk that the generated data may cross regulatory boundaries?

To answer to these questions, eyeforpharma is conducting a virtual round table discussion on December 17^th at 11.30 EST with three industry thought leaders:

• ?Klaus Dugi, Managing Director & Chief Medical Officer, Boehringer Ingelheim
• Immo Zadezensky, Professional Affairs and Stakeholders Engagement, FDA
• Sean Vassilaros, COO - Partner, Thread

Join us on the 17^th at 11.30 am (EST) for this free webinar by registering here: http://goo.gl/R8sGIY

Kind regards,

Nassim

Nassim Azzi
Global Project Director, eyeforpharma
t. 201-234-4804 | c. 240-406-6659 
e. nassim@eyeforpharma.com 
l. www.linkedin.com/in/nassimazzi 

 

To Unsubscribe please click here